Back to top
more

Abeona Therapeutics (ABEO)

(Delayed Data from NSDQ)

$5.98 USD

5.98
676,548

+0.13 (2.22%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $5.97 -0.01 (-0.17%) 4:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

by Zacks Equity Research

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Zacks Equity Research

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

by Zacks Equity Research

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Zacks Equity Research

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

by Zacks Equity Research

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

Zacks Equity Research

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

by Zacks Equity Research

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Zacks Equity Research

Philips' (PHG) Launches a Range of New Products at EuroPCR 2022

by Zacks Equity Research

Philips' (PHG) launches innovative new solutions to attract customers amid a global supply crunch and drive top-line growth.

Zacks Equity Research

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

by Zacks Equity Research

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

Zacks Equity Research

AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals

by Zacks Equity Research

AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

Zacks Equity Research

Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

by Zacks Equity Research

Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates. EPZM has multiple pipeline readouts on track for this year.

Zacks Equity Research

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) posts a wider-than-expected loss for the first quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.

Zacks Equity Research

bluebird (BLUE) Q1 Earnings and Sales Fall Short of Estimates

by Zacks Equity Research

bluebird's (BLUE) Q1 loss is worse than expected while sales lag estimates. It retains its dialogue with the FDA to resolve the clinical hold issue over its pipeline.